Follicular thyroid cancer pathophysiology

Jump to navigation Jump to search

Follicular thyroid cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Follicular thyroid cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Follicular thyroid cancer pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Follicular thyroid cancer pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Follicular thyroid cancer pathophysiology

CDC on Follicular thyroid cancer pathophysiology

Follicular thyroid cancer pathophysiology in the news

Blogs on Follicular thyroid cancer pathophysiology

Directions to Hospitals Treating Follicular thyroid cancer

Risk calculators and risk factors for Follicular thyroid cancer pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Pathogenesis

  • Follicular thyroid cancer is the second most common type of cancer. It constitute about 15% of thyroid cancers.
  • This occurs more commonly in women of over 50 years old. Thyroglobulin (Tg) can be used as a tumor marker for well-differentiated follicular thyroid cancer. Follicular carcinoma tends to metastasize to the lungs and bone via the bloodstream, while papillary thyroid carcinoma commonly metastasizes to cervical lymph nodes.Unlike papillary it metastasises late to lymph nodes, with only 5-10% of patients having nodal metastases at the time of diagnosis. Haematogenous spread is however much more common with 20% or so of patients having distant haematogenous metastases at presentation.

Genetics

  • The Ras oncogene is positive in a significant proportion of individuals. Ras oncogene act through the RAF-MEK-MAPK kinase pathway.
  • Other genes involved in the pathogenesis of follicular thyroid cancer are as follows.
  • RET/PTC (translocation) associated with MAPK and PI3K-AKT signaling pathways
  • HRAS, KRAS, NRAS (mutation) associated with MAPK and PI3K-AKT signaling pathways
  • PAX8/PPARγ (translocation) associated with PAX8-associated nuclear transcription signaling pathways. PAX8 is responsible for follicular cell differentiation.
  • PTEN (mutation) associated with PI3K-AKT signaling pathways
  • PTEN (deletion) associated with PI3K-AKT signaling pathways
  • IDH1 (mutation) assciated with IDH1-associated metabolic pathways signaling pathways
  • Phosphatase and tensin homologue suppressor gene and the phosphatidylinositol 3-kinase pathway are also involved in the pathogenesis of follicular thyroid tumor.
  • p53, c-myc, c-fos, and the thyrotropin (TSH) receptor are some other factors involved in the pathogenesis of follicular thyroid cancer.
  • MicroRNAs namely miR-192, miR-197, miR-328, and miR-346 have increased expression in follicular cell carcinoma.
Schema of key pathways in the development and progression of thyroid cancer.

Associated Conditions

  • Cowden disease
  • Carney complex, type I

Gross Pathology

  • Encapsulated tumors
Gross pathological section of a follicular thyroid carcinoma (tumor at the bottom).

Microscopic Pathology

  • It is not possible to distinguish between follicular adenoma and carcinoma on cytological grounds. If fine needle aspiration cytology (FNAC) suggests follicular neoplasm, thyroid lobectomy should be performed to establish the histopathological diagnosis.
  • Trabecular, solid, follicular tumor cells that invade tumor capsule or surrounding vascular structures.

References